Opentrons announced a $40 million Series E on October 29, led by healthcare investor Avego with participation from BroadOak Capital Partners. The company says the financing will expand its laboratory robotics, software and data infrastructure as it pursues more automated scientific experimentation.
The investment targets a practical gap in AI-assisted research: proposing an experiment is different from physically running it. Opentrons' Flex platform combines liquid-handling robots with software intended to support a cycle of experiment design, execution and revision using the resulting data.
The company plans to invest in AI-driven experimental execution, broader automation capabilities, protocol development and closer integration with other laboratory systems. These are uses of new capital and development priorities; the announcement does not quantify how much has already been spent on each program.
Opentrons reports an installed base of more than 11,000 robots across over 80 countries. That is a company-provided deployment count, rather than an independent measure of active AI-controlled laboratories or validated research productivity.
The financing is material because autonomous-science ambitions require reliable physical execution and usable experimental records as well as capable models. The round is funding, not revenue, and the reviewed announcement does not disclose a valuation. Whether the investment yields faster or more reproducible discoveries will depend on measured results in actual laboratories.